Skip to content

Clinical evaluation of treatment of erectile dysfunction with miao medicine, bamboo technique and moxibustion

Clinical evaluation of treatment of erectile dysfunction with miao medicine, bamboo technique and moxibustion

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051252
Enrollment
Unknown
Registered
2021-09-16
Start date
2021-09-17
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction

Interventions

Sponsors

Guizhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for erectile dysfunction; 2. Medical history >= 3 months, IIEF score between 5-21; 3. Aged 20-55 years; 4. Have a fixed sexual partner for more than 3 months; 5. Have not received any treatment related to this disease within 4 weeks before the test; 6. Serum testosterone level is normal or decreased; 7. Those who have good compliance, agree to participate in the trial, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with obvious organic damage; 2. Patients with severe cardiovascular and cerebrovascular diseases or other liver, kidney, blood, endocrine and mental diseases; 3. The spouse suffers from severe organic disease and cannot fully cooperate; 4. Those who need long-term or are using nitrate drugs; 5. Those who are allergic to the drug in this study.

Design outcomes

Primary

MeasureTime frame
International Erectile Function Questionnaire;

Secondary

MeasureTime frame
TCM clinical syndrome integral;Self-rating Anxiety Scale;Self-rating Depression Scale;

Countries

China

Contacts

Public ContactCui Jin

Guizhou University of Chinese Medicine

775087642@qq.com+86 13985026278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026